jRCT2080222818UnknownPhase 3
A phase III parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPA
Conditions
Trial Snapshot
- Phase
- Phase 3
- Primary Endpoint
- -
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Intervention Model
- Multicenter, randomized, double-blind, parallel group comparison study
Eligibility Criteria
- Ages
- 20age old over to 79age old under (—)
- Sex
- All
Inclusion Criteria
- •Patients diagnosed with Parkinson's disease in stages 2 to 4 on the modified Hoehn & Yahr scale("on" time).
Exclusion Criteria
- •Patients with a history of hypersensitivity to ropinirole.
- •Patients with clinically significant renal impairment or hepatic dysfunction.
- •Patients who have any cutaneous abnormality at the planned application site that could be aggravated by application of the investigational product.
Outcomes
Primary Outcomes
-
Efficacy, and safety.
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Unknown
Phase 3
A parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPAParkinson's diseaseJPRN-jRCT2080222818Hisamitsu Pharmaceutical Co.,Inc.
Unknown
Phase 3
Phase III study of HOB-294 in patients with overactive bladder.Overactive bladderJPRN-jRCT2080221272Hisamitsu Pharmaceutical Co., Inc.
Completed
Not Applicable
Comparative study between parallel groups with placebo for women with daily fatigueJPRN-UMIN000038878Healthcare Systems Co., Ltd.60
Not yet recruiting
Phase 1
Effect of Marma Chikitsa Agnikarma and Physiotherapy in Avabahuka (Frozen shoulder)CTRI/2023/04/051335Datta Meghe Institute Of Medical science
Completed
Not Applicable
Parallel-group comparative study to evaluate the effect of high-dose nicotinamide mononucleotide (NMN) on agingjRCTs03122037362